This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
BioDrugs Open Access 05 August 2023
-
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Drugs in R&D Open Access 22 July 2023
-
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review
BioDrugs Open Access 16 August 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Regulation (EC) 726/2004 of the European Parliament and of the Council. Official J. EU L136/1–L136/33 (2004).
Committee for Medicinal Products for Human Use. Biosimilar Guidelines (accessed 20 July 2011); http://www.ema.europa.eu/htms/human/humanguidelines/multidiscipline.htm
European Commission. Directive 2001/83/EC Art. 10(4) and Part II of the Annex I of Directive 2001/83/EC, as amended. EudraLex, Volume 1, Pharmaceutical legislation medicinal products for human use (accessed 20 July 2011); http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_cons2009/2001_83_cons2009_en.pdf
European Medicines Agency. Guideline on Comparability of Biotechnology-Derived Medicinal Products After a Change in the Manufacturing Process: Non-Clinical and Clinical Issues EMEA/CHMP/BMWP/101695/2006 (EMA, London, 19 July 2007; accessed 20 July 2011) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003935.pdf
Chirino, A.J. & Mire-Sluis, A. Nat. Biotechnol. 22, 1383–1391 (2004).
Schellekens, H. NDT Plus 2 (suppl. 1), i27–i36 (2009).
Brockmeyer, C. & Seidl, A. EJHPPract. 15, 38–44 (2009).
European Medicines Agency. EPARs for authorised medicinal products for human use (accessed 20 July 2011); http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125
Combe, C., Tredree, R.L. & Schellekens, H. Pharmacotherapy 25, 954–962 (2005).
Schmidt, C.A., Ramos, A.S., da Silva, J.E.P., Fronza, M. & Dalmora, S.L. Arq. Bras. Endocrinol. Metabol. 47, 183–189 (2003).
Keithi-Reddy, S.R., Kandasamy, S. & Singh, A.K. Kidney Int. 74, 1617–1622 (2008).
Gray, E. & Mulloy, B. J. Thromb. Haemost. 7, 1218–1221 (2009).
Wenzel, R.G. Am. J. Health Syst. Pharm. 65 (suppl. 6), S9–S15 (2008).
World Health Organization. General information on counterfeit medicines (accessed 20 July 2011) http://www.who.int/medicines/services/counterfeit/overview/en/
Fotiou, F., Aravind, S., Wang, P.P. & Nerapusee, O. Clin. Ther. 31, 336–346 (2009).
Anonymous. Aids Alert 18, 79–80 (2003).
World Health Organization. Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (WHO, Geneva, 2009; accessed 20 July 2011) http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
Federal Drug Administration. Follow-on protein products: regulatory and scientific issues related to developing (accessed 31 May 2011) http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm085854.htm
Patient Protection and Affordable Care Act, as amended by the 111th Congress, H.R. 3590 (accessed 20 July 2011). http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=111_cong_bills&docid=f:h3590enr.txt.pdf
Acknowledgements
The authors wish to thank colleagues from the Biologicals Working Party (BWP), in particular its Chairman, J.-H. Trouvin, for valuable comments on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Weise, M., Bielsky, MC., De Smet, K. et al. Biosimilars—why terminology matters. Nat Biotechnol 29, 690–693 (2011). https://doi.org/10.1038/nbt.1936
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1936
This article is cited by
-
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
BioDrugs (2023)
-
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Drugs in R&D (2023)
-
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review
BioDrugs (2021)
-
Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study
Reproductive Biology and Endocrinology (2020)
-
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
BioDrugs (2020)